CSL has dumped chief executive Paul McKenzie after a brutal year for the global biotechnology giant, installing a former senior manager as interim boss following pressure from shareholders for a leadership overhaul to restore confidence in one of the country’s biggest blue-chips.

CSL shares fell 5 per cent after the company announced McKenzie’s retirement in the final minutes of market trading, leaving investors furious at what they called a mistiming which dragged down the broader market.

Loading…